Abbott Laboratories (NYSE:ABT) shares rose nearly 11% on Thursday after the healthcare company reported second quarter 2026 results that topped Wall Street expectations and raised its full-year adjusted earnings guidance.
The company posted adjusted diluted earnings per share of $1.31 for the quarter, ahead of analyst expectations of $1.28.
Revenue came in at $12.59 billion, slightly above the consensus estimate of $12.52 billion and up 13% on a reported basis from the prior-year period.
On a comparable basis, which excludes the impact of foreign exchange and other specified items, sales increased 4.8% in the second quarter. Abbott reaffirmed its full-year 2026 comparable sales growth outlook of 6.5% to 7.5%.
The company raised its full-year adjusted diluted EPS guidance to a range of $5.45 to $5.60, compared with its previous outlook of $5.38 to $5.58.
Abbott expects third quarter adjusted diluted EPS of $1.38 to $1.46.
“Our second-quarter results reflect the momentum we are building,” Abbott CEO Robert Ford said in a statement. “We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”
The company also highlighted several developments across its medical device and diagnostics businesses. In April, Abbott completed enrollment in its TECTONIC US pivotal trial evaluating its investigational Coronary Intravascular Lithotripsy System, which is designed to treat severe coronary artery calcification before stent implantation.
At the Heart Rhythm Society conference in May, Abbott presented late-breaking data from four clinical trials involving its pulsed field ablation and conduction system pacing technologies. The company also secured CE Mark approval for Libre Duo, a dual glucose-ketone biowearable sensor designed to provide real-time monitoring for people with diabetes.
Abbott additionally submitted its Amulet 360 left atrial appendage device to the US Food and Drug Administration for approval and noted updated colorectal cancer screening guidelines from the American Cancer Society that reaffirmed Cologuard and Cologuard Plus as preferred screening options for average-risk adults aged 45 and older.
During the quarter, Abbott returned $2.1 billion to shareholders through dividends and share repurchases.